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As we approached a new millennium in the year 2000, 6years ago, the hope and expectation was that we would
enter a new era of medical discovery and treatment. Lung
cancer remains the most common cause of cancer death in the
United States and in most other countries around the world.
The anticipation, as we complete the first decade of this new
millennium, is that we will have personalized medicine for
lung cancer. Instead of patients being treated based on their
diagnosis, stage of disease, and perhaps some clinical char-
acteristic such as performance status, with the use of pro-
teomics, DNA microarray, and pharmacogenomics, we will
truly be able to have individualized medicine for patients with
lung cancer.
To a certain degree, this paradigm already exists in
breast cancer, gastrointestinal stromal tumor, myelodysplasia,
and even glioblastoma. Breast cancer genes such as Her-2-
neu and the estrogen receptor were already known and
established as independent prognostic variables and therapeu-
tic targets that can be exploited before this new century and
millennium. Gastrointestinal stromal tumors, such as chronic
myelogenous leukemia, represent somewhat of an aberration
in malignant diseases because there appears to be only a
single molecular abnormality. Drugs such as lenalidomide
provide significant benefit in patients with myelodysplasia
with deletion 5q. In high-grade glioblastoma, the addition of
temozolomide to central nervous system radiotherapy pro-
duced survival benefit, especially in patients with alterations
in the MGMT gene. Thus, there are already examples in
malignant diseases where personalized medicine has dictated
appropriate and novel therapies. For the purpose of this
article, I will discuss lung cancer in two different areas,
metastatic disease and adjuvant therapy, in terms of whether
individualized medicine will make a difference in directing
therapy in the near and distant future.
Treatment results of wet stage IIIB and stage IV disease
remain dismal. During the past 5 years, the modest advances
have primarily been achieved with second-, third-, and even
fourth-line therapy rather than any significant improvement in
first-line therapy. Platinum doublets are superior to best
supportive care and also to single-agent therapy. However,
survival benefit is usually, at most, 2 to 3 months. All
platinum doublets seem comparable. Until recently, there was
no substantive evidence that adding a third drug to a platinum
doublet made a difference in survival. However, a recent
European study suggested a survival benefit to the three-drug
combination of carboplatin plus paclitaxel plus gemcitabine
compared with carboplatin plus paclitaxel alone.
With the sobering data of such minimal benefit, atten-
tion instead has turned to nonchemotherapy molecular tar-
geted agents. Agents such as bexarotene, matrix metallopro-
teinase inhibitors, erlotinib, gefitinib, protein kinase C
inhibitors, and farnesyl transferase inhibitors have all been
subjected to well-designed phase III studies comparing a
platinum doublet to a platinum triplet in which the third drug
was a molecular targeted agent. Almost 9000 patients entered
these phase III studies, all of which were negative (Table 1).
When the Eastern Cooperative Oncology Group 4599 study
opened comparing carboplatin plus paclitaxel versus carbo-
platin plus paclitaxel plus bevacizumab, my opinion at the
time was that this would be yet another negative study similar
to those depicted in Table 1. Furthermore, there were no data
of clinical activity of bevacizumab as a single agent in
non-small cell lung cancer. However, this study, unlike its
predecessors in Table 1, was a positive study. The results are
depicted in Table 2.
We know much more about bevacizumab than we did
several years ago. Phase III studies with this agent have been
positive in colorectal cancer, breast cancer, and renal cell
carcinoma, and the drug appears to have significant activity in
ovarian cancer and probably malignant mesothelioma. In a
study of second-line chemotherapy for breast cancer, in
which survival was the primary endpoint, the comparison of
capecitabine with or without bevacizumab demonstrated
twice the objective response rate but no difference in overall
survival. Bevacizumab is a vascular endothelial growth factor
inhibitor but probably has other known and unknown activ-
ities above and beyond angiogenesis.
Despite the positive results of the Eastern Cooperative
Oncology Group 4599 study, this still just represents a 2.3-
month improvement in median survival. This is somewhat
similar to the survival benefit of a platinum doublet compared
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with best supportive care. However, modest benefits in met-
astatic disease may translate to more meaningful differences
in the adjuvant setting, including improvement in cures.
Before this new century, there was very little optimism that
any form of preoperative or postoperative therapy in resected
non-small cell lung cancer would have an impact on survival.
The first study to show benefit was the International Adjuvant
Lung Trial, which demonstrated a 5% improvement in sur-
vival with long-term follow-up. Postoperative radiotherapy
was allowed in the International Adjuvant Lung Trial study.
Subsequent studies conducted by the National Cancer Insti-
tute of Canada, and by Cancer and Leukemia Group B, for
patients with stage IB through stage IIB actually achieved
double-digit improvements in 4- and 5-year survival on the
order of 10 to 15%. Although with further follow-up the
curves have come together somewhat in the Cancer and
Leukemia Group B study, postoperative platinum doublet
chemotherapy is clearly the standard in patients who are
healthy enough to undergo this therapy following resection.
The challenge for the immediate future will be to
achieve personalized medicine in the adjuvant setting for
patients with non-small cell lung cancer. With the use of
modern molecular techniques, I fully expect in my profes-
sional lifetime that we will be able to better determine those
patients who are already cured with surgery and do not need
any form of adjuvant therapy. In addition, because platinum
remains a cornerstone of adjuvant therapy in this disease, we
should be able to determine which tumors are inherently
platinum resistant and thus would not benefit from adjuvant
platinum-based therapy even if they were destined to relapse
postoperatively. Whether this will allow us to develop an
alternative nonplatinum adjuvant regimen remains to be seen.
This philosophy of using molecular medicine to indi-
vidualize adjuvant therapy has already been applied in breast
cancer. In the nineteenth century, light microscopy was the
only diagnostic tool. In the past several decades, single-gene
predictors with estrogen receptors and Her-2-neu became
available. Now, in the twenty-first century, there are multi-
gene predictors with DNA array and proteomics. A subclas-
sification of breast tumors using this technology has delin-
eated breast cancer into five different types: luminal subtype
A, luminal subtype B, basal-like, ERB-B2, and normal
breast-like. Relapse-free survival and overall survival curves
from phase III clinical trials have demonstrated the validity of
this differentiation. Thus, by determining whether a patient is
positive or negative for estrogen receptor, progesterone re-
ceptor, and Her-2, we can use this type of molecular infor-
mation to determine relapse-free survival and overall survival
in adjuvant treatment of breast cancer. This led to diagnostic
techniques that are used therapeutically, such as Oncotype
DX (Genomic Health, Inc., Redwood City, CA). This allows
the treating physician to predict risk levels as being low risk,
intermediate risk, or high risk based on gene analysis. Using
the previous National Surgical Adjuvant Breast and Bowel
Project node-negative trials, such as B14, which evaluated
adjuvant tamoxifen versus placebo, there was a clear separa-
tion in 10-year rate of recurrence, depending on this molec-
ular analysis. This allows investigators to individualize ther-
apy in this disease.
Similar data were also seen using this analysis with
chemotherapy. This type of molecular analysis now allows
clinicians to realize that most of the chemotherapy benefit in
the National Surgical Adjuvant Breast and Bowel Project
B-20 study comparing tamoxifen versus tamoxifen plus che-
motherapy was in the high-risk molecular group, with little or
no benefit in the low-risk and intermediate-risk groups.
Breast cancer physicians can now use this molecular infor-
mation and recommend adjuvant chemotherapy to only those
postmenopausal patients who will truly benefit from this
therapeutic approach, the high-risk group.
We truly are in a new century and millennium. On a
personal note, I was a fellow at M. D. Anderson Cancer
Center in 1973, and during that time, we saw the introduction
of many exciting chemotherapy agents, including doxorubi-
cin and cisplatin. These two drugs have stood the test of time
and, over 30 years later, are still widely used. However, I feel
that these are even more exciting times for new drug devel-
opment. We are at the threshold of using molecular diagnos-
tics to determine who does and does not need therapy and
using this new technology to develop targeted agents that will
truly make a major difference in cancer treatment. I do not
expect that we will “eliminate the pain and suffering from
cancer” by the year 2015, but I fully expect the landscape to
look much improved by that arbitrary time point. By the year
2015, I expect that we will be using personalized medicine to
determine who does and does not need adjuvant therapy in
lung cancer. Optimistically, we may also have personalized
medicine to have improved directed therapy for our patients
TABLE 1. Phase III Targeted Therapies
Agent No. of Patients
Bexarotene 1200
MMPI 2000
Erlotinib 2000
Gefitinib 2000
PKC inhibitor 1000
Lonafarnib (FTI) 700
MMPI, matrix metalloproteinase inhibitor; PKC, protein kinase C; FFI, farnesyl
transferase inhibitor.
TABLE 2. Eastern Cooperative Oncology Group 4599 Study
Results
Carboplatin 
Paclitaxel
Carboplatin 
Paclitaxel 
Bevacizumab p Value
No. of patients 444 434
Response rate (%) 10 26  0.0001
PFS (mo) 4.5 6.4  0.0001
MST (mo) 10.2 12.5 0.0075
1-year survival (%) 43.7 51.9
2-year survival (%) 16.9 22.1
PFS, progression-free survival; MST, median survival time.
L. H. Einhorn Journal of Thoracic Oncology • Volume 1, Number 7, September 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer738
with resected non-small cell lung cancer. I remain somewhat
more pessimistic about metastatic disease. During the past 20
years, there has been clear and unequivocal evidence of
improvement in quality of life and quantity of survival.
Furthermore, therapy has been better tolerated with the ad-
vent of improved supportive care, especially antiemetics.
Whether the year 2015 will see further modest improvement
measured in months or more spectacular results remains to be
seen. Either way, these are exciting times for both cancer
researchers and our patients with lung cancer.
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